Summit hits first milestone in Duchenne muscular dystrophy program

2nd December 2015

Nasdaq-listed Oxford spinout Summit Therapeutics has hit its first research milestone as part of a multiyear strategic alliance with the University of Oxford. The collaboration is focussed on developing future-generation utrophin modulators for the potential treatment of all patients with the progressive muscle wasting disorder Duchenne Muscular Dystrophy.

For further information please see the company’s announcement.

Press release sign up